Cellectis S.A. is a clinical-stage biopharmaceutical company specializing in the development of next-generation immunotherapies for cancer. With over 25 years of innovation, Cellectis leverages its proprietary TALEN® gene-editing technology to engineer chimeric antigen receptor (CAR) T-cells, creating "off-the-shelf" allogeneic therapies designed to be widely accessible to cancer patients. Unlike traditional personalized cell therapies, these products use donor-derived cells, aiming to reduce manufacturing times and improve scalability.

Cellectis’ product pipeline targets a range of hematologic malignancies, including acute lymphoblastic leukemia, acute myeloid leukemia, non-Hodgkin lymphoma, and multiple myeloma. The company operates significant research and manufacturing infrastructure, enabling end-to-end control over the cell and gene therapy value chain. Strategic collaborations with global biotechnology and pharmaceutical partners help advance its programs and expand the reach of its platform technology. Headquartered in Paris with additional presence in New York, Cellectis holds a robust intellectual property portfolio and is recognized as a pioneer in the field of genome editing and cellular immunotherapy.